Leiner Looks For Ibuprofen Growth Following “Negative Mix Impact”
This article was originally published in The Tan Sheet
Executive Summary
Increased ibuprofen opportunities from the planned acquisition of Pharmaceutical Formulations, Inc. (PFI) will help build Leiner's pain management category to $200 mil. by the end of the year, CEO Bob Kaminski claimed Aug. 10